Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
10 search results for:

Risankizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-01-2022 | Psoriatic arthritis | News | Article
    approvalsWatch

    FDA approves risankizumab for psoriatic arthritis

    Risankizumab may be used alone or in combination with nonbiologic DMARDs.

    Author:
    Claire Barnard
  2. 20-10-2021 | Psoriatic arthritis | News | Article
    approvalsWatch

    EMA recommends expanding risankizumab indication to include PsA

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended  that the indication for the interleukin (IL)-23 inhibitor risankizumab be extended to include psoriatic arthritis (PsA).

    Author:
    Shreeya Nanda
  3. 06-11-2021 | ACR 2021 | Conference coverage | Article

    KEEPsAKE trials show benefits of risankizumab in patients with PsA

    Treatment with the IL-23 inhibitor risankizumab may improve outcomes for patients with psoriatic arthritis, suggests an integrated analysis of data from the KEEPsAKE 1 and 2 studies presented at the ACR Convergence 2021 virtual meeting.

    Author:
    Claire Barnard
    Published in:
    ACR Convergence 2021; 3–9 November
  4. play
    07-11-2021 | ACR 2021 | Conference coverage | Video

    Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

    Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis.

  5. 04-06-2021 | EULAR 2021 | Conference coverage | Article

    KEEPsAKE 2 supports risankizumab for the treatment of PsA

    The IL-23 inhibitor risankizumab is a promising treatment option for psoriatic arthritis, suggest results from the KEEPsAKE 2 trial presented at the EULAR 2021 Virtual Congress.

    Author:
    Claire Barnard
    Published in:
    EULAR 2021 Virtual Congress; 2–5 June
  6. play
    04-06-2021 | EULAR 2021 | Conference coverage | Video

    Risankizumab shows promise for PsA in the KEEPsAKE 2 trial

    Andrew Östör talks about the results of KEEPsAKE 2, a phase 3 trial of risankizumab versus placebo in patients with psoriatic arthritis, and explores how the IL-23 inhibitor may impact clinical practice if approved by the regulatory authorities.

  7. 27-06-2018 | Ankylosing spondylitis | News | Article

    Risankizumab disappoints in ankylosing spondylitis trial

    Patients with ankylosing spondylitis who are treated with the interleukin-23 inhibitor risankizumab do not experience clinically meaningful improvements in the signs and symptoms of disease, phase II study results suggest.

    Published in:
    Ann Rheum Dis 2018; Advance online publication
  8. 16-06-2018 | Psoriatic arthritis | EULAR 2018 | Article

    Benefits of risankizumab maintained for 24 weeks in patients with PsA

    Study results presented at the EULAR 2018 meeting in Amsterdam, the Netherlands, indicate that improvements in joint and skin symptoms seen with risankizumab treatment are maintained for 24 weeks among patients with psoriatic arthritis.

    Published in:
    EULAR 2018 meeting; Amsterdam, the Netherlands
  9. 14-11-2017 | Psoriatic arthritis | News | Article

    Risankizumab may improve joint and skin symptoms in PsA patients

    Results of a dose-ranging phase II trial support further investigation of the interleukin-23 inhibitor risankizumab for the treatment of psoriatic arthritis.

  10. 21-02-2019 | Psoriatic arthritis | Feature | Article

    The role of JAK inhibitors in the treatment of PsA

    She adds that the IL-23 specific inhibitors guselkumab and tildrakizumab, which are currently approved for the treatment of psoriasis, along with the IL-23 inhibitors risankizumab and mirikizumab that are presently under investigation, “work very well for skin and their effect on the joints is currently being evaluated.”

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.